Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Neurogastroenterol Motil. 2023 Aug;35(8):e14645. doi: 10.1111/nmo.14645. Epub 2023 Jul 4.
Treatment of gastrointestinal pain remains a significant challenge in the management of many disorders of gut-brain interaction (DGBI). Pharmacologic agents and various behavioral therapies are among the potential therapeutic options for pain-predominant DGBI such as irritable bowel syndrome, functional dyspepsia, functional heartburn, and centrally mediated abdominal pain syndrome. In the retrospective study published in this journal, Luo et al. examine the use of prescription pain medications from a global perspective among patients with DGBI using the Rome Foundation Global Epidemiology Study. This review article provides an overview of usage patterns of various pharmacologic pain management agents (opioids, central neuromodulators, antispasmodics, and other peripherally acting agents) and non-pharmacologic therapies in the context of clinical practice recommendations on the management of DGBI pain.
胃肠道疼痛的治疗仍然是许多肠脑相互作用障碍（DGBI）管理中的重大挑战。对于以疼痛为主要表现的 DGBI，如肠易激综合征、功能性消化不良、功能性烧心和中枢介导的腹痛综合征，药物治疗和各种行为疗法都是潜在的治疗选择。在本期杂志发表的回顾性研究中，Luo 等人使用罗马基金会全球流行病学研究，从全球角度检查了 DGBI 患者使用处方止痛药的情况。这篇综述文章概述了各种药物治疗疼痛管理药物（阿片类药物、中枢神经调节剂、抗痉挛药和其他外周作用药物）和非药物治疗的使用模式，并结合了 DGBI 疼痛管理的临床实践建议。
